Chronic respiratory infection by Pseudomonas aeruginosa contributessignificantly to the morbidity and mortality associated with cystic fibrosis (CF).Using a series of phenotypic and genotypic tests on collections of 40 isolatesper sputum sample, we analysed fluctuations within sputum populations of the P. aeruginosa Liverpool epidemic strain (LES) during pulmonaryexacerbations. For each of three patients, three sequential sputum sampleswere analysed: (1) on presentation with exacerbation at the RegionalAdult Cystic Fibrosis Unit, Liverpool; (2) a few days into intravenousantibiotic treatment; (3) when the patient had recovered. Fluctuationswere observed in morphotype distribution, the production of virulence-associatedquorum-sensing-dependent exoproducts (the phenazine compound pyocyaninand the elastase LasA), antibiotic susceptibility profiles and levelsof auxotrophy. PCR assays were used to screen isolates for the presence ofnovel regions of the LES genome (islands and prophages) and to detectfree phages. In one patient there was an increase in the prevalence of theLESGI-5 genomic island during the sampling period from 10 to 97.5 %carriage. LES phages 2–4 were detected in either the majority or allsputum samples tested, indicating widespread phage activity during the samplingperiod. The results of this study are indicative that significant fluctuationsoccur within P. aeruginosa populations during short periods of pulmonaryexacerbation and intravenous antibiotic therapy.
Al-AloulM.,
CrawleyJ.,
WinstanleyC.,
HartC. A.,
LedsonM. J.,
WalshawM. J.2004; Increased morbidityassociated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax 59:334–336[CrossRef]
AndrewsJ. M. for the BSAC Working Party on SusceptibilityTesting.2001; BSAC standardized disc susceptibilitytesting method. J Antimicrob Chemother 48 (Suppl. S1):43–57[CrossRef]
BolesB. R.,
SinghP. K.2008; Endogenous oxidative stress produces diversity and adaptability in biofilmcommunities. Proc Natl Acad Sci U S A 105:12503–12508[CrossRef]
CabralD. A.,
LohB. A.,
SpeertD. P.1987; Mucoid Pseudomonas aeruginosa resists nonopsonicphagocytosis by human neutrophils and macrophages. Pediatr Res 22:429–431[CrossRef]
CiofuO.,
RiisB.,
PresslerT.,
PoulsenH. E.,
HøibyN.2005; Occurrence of hypermutable Pseudomonasaeruginosa in cystic fibrosis patients is associated with the oxidativestress caused by chronic lung inflammation. Antimicrob Agents Chemother 49:2276–2282[CrossRef]
De VosD.,
LimA.Jr,
PirnayJ. P.,
DuinslaegerL.,
RevetsH.,
VanderkelenA.,
HamersR.,
CornelisP.1997; Analysis of epidemic Pseudomonas aeruginosa isolates by isoelectricfocusing of pyoverdine and RAPD-PCR: modern tools for an integrated anti-nosocomialinfection strategy in burn wound centres. Burns 23:379–386[CrossRef]
FowerakerJ. E.,
LaughtonC. R.,
BrownD. F.,
BiltonD.2005; Phenotypic variability of Pseudomonasaeruginosa in sputa from patients with acute infective exacerbation ofcystic fibrosis and its impact on the validity of antimicrobial susceptibilitytesting. J Antimicrob Chemother 55:921–927[CrossRef]
GovanJ. R.,
FyfeJ. A.1978).Mucoid; Pseudomonas aeruginosa and cystic fibrosis: resistance ofthe mucoid from to carbenicillin, flucloxacillin and tobramycin and the isolationof mucoid variants in vitro. J Antimicrob Chemother 4:233–240[CrossRef]
GuzelC. B.,
GercekerA. A.2008; In vitro activities of various antibiotics, alone and in combinationwith colistin methanesulfonate, against Pseudomonas aeruginosa strainsisolated from cystic fibrosis patients. Chemotherapy 54:147–151[CrossRef]
HyattJ. M.,
SchentagJ. J.2000; Pharmacodynamic modeling of risk factors for ciprofloxacin resistancein Pseudomonas aeruginosa
. Infect Control Hosp Epidemiol 21:S9–S11[CrossRef]
MatheeK.,
CiofuO.,
SternbergC.,
LindumP. W.,
CampbellJ. I.,
JensenP.,
JohnsenA. H.,
GivskovM.,
OhmanD. E.other authors1999; Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cysticfibrosis lung. Microbiology 145:1349–1357[CrossRef]
MohanK.,
FothergillJ. L.,
StorrarJ.,
LedsonM. J.,
WinstanleyC.,
WalshawM. J.2008; Transmission of Pseudomonas aeruginosa epidemic strain from a patient with cystic fibrosisto a pet cat. Thorax 63:839–840[CrossRef]
NakajimaA.,
SugimotoY.,
YoneyamaH.,
NakaeT.2002; High-level fluoroquinolone resistance in Pseudomonasaeruginosa due to interplay of the MexAB-OprM efflux pump and the DNAgyrase mutation. Microbiol Immunol 46:391–395[CrossRef]
NigaT.,
ItoH.,
OyamadaY.,
YamagishiJ.,
KadonoM.,
NishinoT.,
GotohN.,
InoueM.2005; Cooperationbetween alteration of DNA gyrase genes and over-expression of MexB and MexXconfers high-level fluoroquinolone resistance in Pseudomonas aeruginosa strains isolated from a patient who received a liver transplant followedby treatment with fluoroquinolones. Microbiol Immunol 49:443–446[CrossRef]
OliverA.,
CantonR.,
CampoP.,
BaqueroF.,
BlazquezJ.2000; High frequency of hypermutable Pseudomonasaeruginosa in cystic fibrosis lung infection. Science 288:1251–1254[CrossRef]
ParsonsY. N.,
PanageaS.,
SmartC. H.,
WalshawM. J.,
HartC. A.,
WinstanleyC.2002; Use of subtractivehybridization to identify a diagnostic probe for a cystic fibrosis epidemicstrain of Pseudomonas aeruginosa
. J Clin Microbiol 40:4607–4611[CrossRef]
PlasenciaV.,
BorrellN.,
MaciaM. D.,
MoyaB.,
PerezJ.L.,
OliverA.2007; Influence of high mutationrates on the mechanisms and dynamics of in vitro and in vivo resistance developmentto single or combined antipseudomonal agents. Antimicrob AgentsChemother 51:2574–2581
RegelmannW. E.,
ElliottG. R.,
WarwickW. J.,
ClawsonC. C.1990; Reduction of sputum Pseudomonasaeruginosa density by antibiotics improves lung function in cystic fibrosismore than do bronchodilators and chest physiotherapy alone. AmRev Respir Dis 141:914–921
RolainJ. M.,
FrancoisP.,
HernandezD.,
BittarF.,
RichetH.,
FournousG.,
MattenbergerY.,
BosdureE.,
StremlerN.,
otherauthors.2009; Genomic analysis of an emerging multiresistant Staphylococcus aureus strain rapidly spreading in cystic fibrosis patientsrevealed the presence of an antibiotic inducible bacteriophage. Biol Direct 4:1[CrossRef]
ScottF. W.,
PittT. L.2004).Identification; and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales. J Med Microbiol 53:609–615[CrossRef]
SmartC. H.,
WalshawM. J.,
HartC. A.,
WinstanleyC.2006; Use of suppression subtractive hybridizationto examine the accessory genome of the Liverpool cystic fibrosis epidemicstrain of Pseudomonas aeruginosa
. J Med Microbiol 55:677–688[CrossRef]
SmithA. L.,
FielS. B.,
Mayer-HamblettN,
RamseyB,
BurnsJ. L.2003; Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibioticadministration: lack of association in cystic fibrosis. Chest 123:1495–1502[CrossRef]
SmithE. E.,
BuckleyD. G.,
WuZ.,
SaenphimmachakC.,
HoffmanL. R.,
D'ArgenioD. A.,
MillerS. I.,
RamseyB. W.,
SpeertD. P. &other authors; 2006; Genetic adaptation by Pseudomonasaeruginosa to the airways of cystic fibrosis patients. ProcNatl Acad Sci U S A 103:8487–8492
ThomasS. R.,
RayA.,
HodsonM. E.,
PittT. L.2000; Increased sputum amino acid concentrations and auxotrophyof Pseudomonas aeruginosa in severe cystic fibrosis lung disease. Thorax 55:795–797[CrossRef]
WinstanleyC.,
FothergillJ. L.2009; The role of quorum sensing in chronic cystic fibrosis Pseudomonasaeruginosa infections. FEMS Microbiol Lett 290:1–9[CrossRef]
WinstanleyC.,
LangilleM. G. I.,
FothergillJ. L.,
Kukavica-IbruljI.,
Paradis-BleauC.,
SanschagrinF.,
ThomsonN. R.,
WinsorG. L.,
QuailM. A.other authors2009; Newly introducedgenomic prophage islands are critical determinants of in vivo competitivenessin the Liverpool epidemic strain of Pseudomonas aeruginosa
. Genome Res 19:12–23